The lack of an association between IL-33 and overall glycemia in individuals with prediabetes may point toward a potential dysfunction in the IL-33/ST2 axis that may occur early during the development of metabolic disorders/T2D and its potential reversal with glucose-lowering medications as may be occurring in individuals with T2D. This evidence concerns the gene IL33 and prediabetes syndrome.